nodes	percent_of_prediction	percent_of_DWPC	metapath
Thioridazine—ADRA1B—vas deferens—urinary bladder cancer	0.082	0.273	CbGeAlD
Thioridazine—HTR7—vas deferens—urinary bladder cancer	0.0478	0.159	CbGeAlD
Thioridazine—CYP2E1—Etoposide—urinary bladder cancer	0.0444	0.185	CbGbCtD
Thioridazine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0397	0.166	CbGbCtD
Thioridazine—CYP2C8—Etoposide—urinary bladder cancer	0.0332	0.138	CbGbCtD
Thioridazine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0308	0.128	CbGbCtD
Thioridazine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0277	0.116	CbGbCtD
Thioridazine—CYP1A2—Etoposide—urinary bladder cancer	0.0257	0.107	CbGbCtD
Thioridazine—CYP2C9—Cisplatin—urinary bladder cancer	0.0235	0.0983	CbGbCtD
Thioridazine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0144	0.0602	CbGbCtD
Thioridazine—CYP2C19—urine—urinary bladder cancer	0.0116	0.0387	CbGeAlD
Thioridazine—CYP1A2—urine—urinary bladder cancer	0.00948	0.0316	CbGeAlD
Thioridazine—CYP2C9—urine—urinary bladder cancer	0.009	0.03	CbGeAlD
Thioridazine—CYP2E1—urine—urinary bladder cancer	0.00853	0.0284	CbGeAlD
Thioridazine—HTR2A—urine—urinary bladder cancer	0.00741	0.0247	CbGeAlD
Thioridazine—CYP2D6—urine—urinary bladder cancer	0.00675	0.0225	CbGeAlD
Thioridazine—CHRM2—prostate gland—urinary bladder cancer	0.0055	0.0183	CbGeAlD
Thioridazine—ADRA1B—renal system—urinary bladder cancer	0.00499	0.0166	CbGeAlD
Thioridazine—ADRA1A—prostate gland—urinary bladder cancer	0.00411	0.0137	CbGeAlD
Thioridazine—KCNH2—prostate gland—urinary bladder cancer	0.00397	0.0132	CbGeAlD
Thioridazine—KCNH2—seminal vesicle—urinary bladder cancer	0.00336	0.0112	CbGeAlD
Thioridazine—HRH1—prostate gland—urinary bladder cancer	0.00319	0.0106	CbGeAlD
Thioridazine—HTR7—epithelium—urinary bladder cancer	0.00313	0.0104	CbGeAlD
Thioridazine—ADRA2A—prostate gland—urinary bladder cancer	0.00313	0.0104	CbGeAlD
Thioridazine—CYP2E1—prostate gland—urinary bladder cancer	0.00306	0.0102	CbGeAlD
Thioridazine—HTR1A—renal system—urinary bladder cancer	0.00304	0.0101	CbGeAlD
Thioridazine—ADRA1A—epithelium—urinary bladder cancer	0.00302	0.0101	CbGeAlD
Thioridazine—HTR7—smooth muscle tissue—urinary bladder cancer	0.00302	0.0101	CbGeAlD
Thioridazine—HTR7—renal system—urinary bladder cancer	0.00291	0.00969	CbGeAlD
Thioridazine—HTR2C—female reproductive system—urinary bladder cancer	0.00289	0.00965	CbGeAlD
Thioridazine—ADRA1A—renal system—urinary bladder cancer	0.0028	0.00935	CbGeAlD
Thioridazine—KCNH2—renal system—urinary bladder cancer	0.00271	0.00903	CbGeAlD
Thioridazine—KCNH2—urethra—urinary bladder cancer	0.00266	0.00887	CbGeAlD
Thioridazine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00265	0.00882	CbGeAlD
Thioridazine—CYP2E1—seminal vesicle—urinary bladder cancer	0.00259	0.00863	CbGeAlD
Thioridazine—CYP2C8—renal system—urinary bladder cancer	0.00248	0.00826	CbGeAlD
Thioridazine—HRH1—epithelium—urinary bladder cancer	0.00234	0.0078	CbGeAlD
Thioridazine—HTR7—female reproductive system—urinary bladder cancer	0.00233	0.00776	CbGeAlD
Thioridazine—CYP1A2—renal system—urinary bladder cancer	0.00232	0.00773	CbGeAlD
Thioridazine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00226	0.00752	CbGeAlD
Thioridazine—KCNH2—female reproductive system—urinary bladder cancer	0.00217	0.00723	CbGeAlD
Thioridazine—HRH1—urethra—urinary bladder cancer	0.00213	0.00711	CbGeAlD
Thioridazine—ADRA2A—urethra—urinary bladder cancer	0.00209	0.00698	CbGeAlD
Thioridazine—CYP2E1—renal system—urinary bladder cancer	0.00209	0.00695	CbGeAlD
Thioridazine—CYP2C19—vagina—urinary bladder cancer	0.00206	0.00685	CbGeAlD
Thioridazine—CYP2E1—urethra—urinary bladder cancer	0.00205	0.00683	CbGeAlD
Thioridazine—CYP2C8—female reproductive system—urinary bladder cancer	0.00198	0.00662	CbGeAlD
Thioridazine—KCNH2—vagina—urinary bladder cancer	0.00196	0.00654	CbGeAlD
Thioridazine—HTR2A—epithelium—urinary bladder cancer	0.00195	0.00652	CbGeAlD
Thioridazine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00188	0.00628	CbGeAlD
Thioridazine—HTR2A—renal system—urinary bladder cancer	0.00181	0.00604	CbGeAlD
Thioridazine—CYP2C8—vagina—urinary bladder cancer	0.0018	0.00598	CbGeAlD
Thioridazine—CYP2C9—female reproductive system—urinary bladder cancer	0.00176	0.00588	CbGeAlD
Thioridazine—HRH1—female reproductive system—urinary bladder cancer	0.00174	0.0058	CbGeAlD
Thioridazine—ADRA2A—female reproductive system—urinary bladder cancer	0.00171	0.00569	CbGeAlD
Thioridazine—CYP2E1—female reproductive system—urinary bladder cancer	0.00167	0.00557	CbGeAlD
Thioridazine—CYP2D6—renal system—urinary bladder cancer	0.00165	0.00551	CbGeAlD
Thioridazine—HRH1—vagina—urinary bladder cancer	0.00157	0.00524	CbGeAlD
Thioridazine—ADRA2A—vagina—urinary bladder cancer	0.00154	0.00515	CbGeAlD
Thioridazine—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00153	0.00508	CcSEcCtD
Thioridazine—Eosinophilia—Fluorouracil—urinary bladder cancer	0.00151	0.005	CcSEcCtD
Thioridazine—Ventricular arrhythmia—Doxorubicin—urinary bladder cancer	0.00148	0.0049	CcSEcCtD
Thioridazine—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00147	0.00488	CcSEcCtD
Thioridazine—Cardiac arrest—Etoposide—urinary bladder cancer	0.00145	0.00483	CcSEcCtD
Thioridazine—HTR2A—female reproductive system—urinary bladder cancer	0.00145	0.00484	CbGeAlD
Thioridazine—Pancytopenia—Fluorouracil—urinary bladder cancer	0.00144	0.0048	CcSEcCtD
Thioridazine—Diarrhoea—Mitomycin—urinary bladder cancer	0.00142	0.00472	CcSEcCtD
Thioridazine—Blood disorder—Epirubicin—urinary bladder cancer	0.00141	0.00469	CcSEcCtD
Thioridazine—Sweating increased—Cisplatin—urinary bladder cancer	0.0014	0.00466	CcSEcCtD
Thioridazine—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.00139	0.00461	CcSEcCtD
Thioridazine—Pancytopenia—Cisplatin—urinary bladder cancer	0.00137	0.00455	CcSEcCtD
Thioridazine—Amenorrhoea—Epirubicin—urinary bladder cancer	0.00134	0.00446	CcSEcCtD
Thioridazine—CYP2D6—female reproductive system—urinary bladder cancer	0.00132	0.00441	CbGeAlD
Thioridazine—Vomiting—Mitomycin—urinary bladder cancer	0.00132	0.00439	CcSEcCtD
Thioridazine—Arrhythmia—Thiotepa—urinary bladder cancer	0.00131	0.00437	CcSEcCtD
Thioridazine—HTR2A—vagina—urinary bladder cancer	0.00131	0.00438	CbGeAlD
Thioridazine—Rash—Mitomycin—urinary bladder cancer	0.00131	0.00435	CcSEcCtD
Thioridazine—Dermatitis—Mitomycin—urinary bladder cancer	0.00131	0.00435	CcSEcCtD
Thioridazine—Blood disorder—Doxorubicin—urinary bladder cancer	0.00131	0.00434	CcSEcCtD
Thioridazine—Headache—Mitomycin—urinary bladder cancer	0.0013	0.00433	CcSEcCtD
Thioridazine—Mental disorder—Thiotepa—urinary bladder cancer	0.00129	0.00428	CcSEcCtD
Thioridazine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00129	0.00427	CcSEcCtD
Thioridazine—Sweating increased—Etoposide—urinary bladder cancer	0.00129	0.00427	CcSEcCtD
Thioridazine—Erythema—Thiotepa—urinary bladder cancer	0.00128	0.00425	CcSEcCtD
Thioridazine—KCNH2—lymph node—urinary bladder cancer	0.00127	0.00423	CbGeAlD
Thioridazine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00127	0.0042	CcSEcCtD
Thioridazine—Pancytopenia—Etoposide—urinary bladder cancer	0.00125	0.00416	CcSEcCtD
Thioridazine—Amenorrhoea—Doxorubicin—urinary bladder cancer	0.00124	0.00413	CcSEcCtD
Thioridazine—Nausea—Mitomycin—urinary bladder cancer	0.00124	0.0041	CcSEcCtD
Thioridazine—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.00122	0.00405	CcSEcCtD
Thioridazine—Vision blurred—Thiotepa—urinary bladder cancer	0.00121	0.00401	CcSEcCtD
Thioridazine—Anaemia—Thiotepa—urinary bladder cancer	0.00118	0.00393	CcSEcCtD
Thioridazine—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00118	0.00393	CcSEcCtD
Thioridazine—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00118	0.00392	CcSEcCtD
Thioridazine—Agitation—Thiotepa—urinary bladder cancer	0.00118	0.00391	CcSEcCtD
Thioridazine—Dermatitis contact—Epirubicin—urinary bladder cancer	0.00117	0.00387	CcSEcCtD
Thioridazine—Abnormal dreams—Epirubicin—urinary bladder cancer	0.00117	0.00387	CcSEcCtD
Thioridazine—Jaundice—Etoposide—urinary bladder cancer	0.00115	0.00381	CcSEcCtD
Thioridazine—Leukopenia—Thiotepa—urinary bladder cancer	0.00115	0.00381	CcSEcCtD
Thioridazine—Gynaecomastia—Methotrexate—urinary bladder cancer	0.00113	0.00375	CcSEcCtD
Thioridazine—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.00111	0.00368	CcSEcCtD
Thioridazine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.00111	0.00367	CcSEcCtD
Thioridazine—Agranulocytosis—Etoposide—urinary bladder cancer	0.0011	0.00365	CcSEcCtD
Thioridazine—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.00109	0.00363	CcSEcCtD
Thioridazine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.00109	0.00361	CcSEcCtD
Thioridazine—Abnormal dreams—Doxorubicin—urinary bladder cancer	0.00108	0.00358	CcSEcCtD
Thioridazine—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.00108	0.00358	CcSEcCtD
Thioridazine—Erythema—Gemcitabine—urinary bladder cancer	0.00108	0.00358	CcSEcCtD
Thioridazine—Erythema—Fluorouracil—urinary bladder cancer	0.00106	0.00352	CcSEcCtD
Thioridazine—Confusional state—Thiotepa—urinary bladder cancer	0.00105	0.0035	CcSEcCtD
Thioridazine—Photosensitivity—Methotrexate—urinary bladder cancer	0.00104	0.00346	CcSEcCtD
Thioridazine—Arrhythmia—Cisplatin—urinary bladder cancer	0.00103	0.00342	CcSEcCtD
Thioridazine—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00103	0.0034	CcSEcCtD
Thioridazine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00102	0.0034	CcSEcCtD
Thioridazine—Tachycardia—Thiotepa—urinary bladder cancer	0.00102	0.00339	CcSEcCtD
Thioridazine—HRH1—lymph node—urinary bladder cancer	0.00102	0.00339	CbGeAlD
Thioridazine—Erythema—Cisplatin—urinary bladder cancer	0.001	0.00334	CcSEcCtD
Thioridazine—ADRA2A—lymph node—urinary bladder cancer	0.000999	0.00333	CbGeAlD
Thioridazine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000999	0.00332	CcSEcCtD
Thioridazine—Anorexia—Thiotepa—urinary bladder cancer	0.000997	0.00331	CcSEcCtD
Thioridazine—Anaemia—Gemcitabine—urinary bladder cancer	0.000996	0.00331	CcSEcCtD
Thioridazine—Anaemia—Fluorouracil—urinary bladder cancer	0.000979	0.00325	CcSEcCtD
Thioridazine—Photosensitivity—Epirubicin—urinary bladder cancer	0.000976	0.00324	CcSEcCtD
Thioridazine—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.00097	0.00322	CcSEcCtD
Thioridazine—Leukopenia—Gemcitabine—urinary bladder cancer	0.000965	0.0032	CcSEcCtD
Thioridazine—Leukopenia—Fluorouracil—urinary bladder cancer	0.000949	0.00315	CcSEcCtD
Thioridazine—Vision blurred—Cisplatin—urinary bladder cancer	0.000947	0.00314	CcSEcCtD
Thioridazine—Tremor—Cisplatin—urinary bladder cancer	0.000941	0.00313	CcSEcCtD
Thioridazine—Lethargy—Methotrexate—urinary bladder cancer	0.000934	0.0031	CcSEcCtD
Thioridazine—Somnolence—Thiotepa—urinary bladder cancer	0.00093	0.00309	CcSEcCtD
Thioridazine—Anaemia—Cisplatin—urinary bladder cancer	0.000928	0.00308	CcSEcCtD
Thioridazine—Decreased appetite—Thiotepa—urinary bladder cancer	0.000909	0.00302	CcSEcCtD
Thioridazine—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000908	0.00301	CcSEcCtD
Thioridazine—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000903	0.003	CcSEcCtD
Thioridazine—Leukopenia—Cisplatin—urinary bladder cancer	0.000899	0.00299	CcSEcCtD
Thioridazine—Constipation—Thiotepa—urinary bladder cancer	0.000894	0.00297	CcSEcCtD
Thioridazine—Oedema—Gemcitabine—urinary bladder cancer	0.00088	0.00292	CcSEcCtD
Thioridazine—Lethargy—Epirubicin—urinary bladder cancer	0.000874	0.0029	CcSEcCtD
Thioridazine—Confusional state—Fluorouracil—urinary bladder cancer	0.000872	0.0029	CcSEcCtD
Thioridazine—Oedema—Fluorouracil—urinary bladder cancer	0.000865	0.00287	CcSEcCtD
Thioridazine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000862	0.00286	CcSEcCtD
Thioridazine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000861	0.00286	CcSEcCtD
Thioridazine—Anaemia—Etoposide—urinary bladder cancer	0.000851	0.00282	CcSEcCtD
Thioridazine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00085	0.00282	CcSEcCtD
Thioridazine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000847	0.00281	CcSEcCtD
Thioridazine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000844	0.0028	CcSEcCtD
Thioridazine—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.00084	0.00279	CcSEcCtD
Thioridazine—Anorexia—Gemcitabine—urinary bladder cancer	0.000838	0.00278	CcSEcCtD
Thioridazine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000827	0.00274	CcSEcCtD
Thioridazine—Anorexia—Fluorouracil—urinary bladder cancer	0.000824	0.00274	CcSEcCtD
Thioridazine—Leukopenia—Etoposide—urinary bladder cancer	0.000824	0.00274	CcSEcCtD
Thioridazine—Hypotension—Gemcitabine—urinary bladder cancer	0.000822	0.00273	CcSEcCtD
Thioridazine—Oedema—Cisplatin—urinary bladder cancer	0.00082	0.00272	CcSEcCtD
Thioridazine—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000815	0.0027	CcSEcCtD
Thioridazine—Lethargy—Doxorubicin—urinary bladder cancer	0.000809	0.00269	CcSEcCtD
Thioridazine—Hypotension—Fluorouracil—urinary bladder cancer	0.000808	0.00268	CcSEcCtD
Thioridazine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000803	0.00267	CcSEcCtD
Thioridazine—Tachycardia—Cisplatin—urinary bladder cancer	0.0008	0.00266	CcSEcCtD
Thioridazine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000793	0.00263	CcSEcCtD
Thioridazine—Asthma—Methotrexate—urinary bladder cancer	0.000791	0.00263	CcSEcCtD
Thioridazine—Eosinophilia—Methotrexate—urinary bladder cancer	0.000783	0.0026	CcSEcCtD
Thioridazine—Somnolence—Gemcitabine—urinary bladder cancer	0.000782	0.0026	CcSEcCtD
Thioridazine—Anorexia—Cisplatin—urinary bladder cancer	0.000781	0.00259	CcSEcCtD
Thioridazine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00077	0.00256	CcSEcCtD
Thioridazine—Somnolence—Fluorouracil—urinary bladder cancer	0.000769	0.00255	CcSEcCtD
Thioridazine—Hypotension—Cisplatin—urinary bladder cancer	0.000766	0.00254	CcSEcCtD
Thioridazine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000765	0.00254	CcSEcCtD
Thioridazine—Confusional state—Etoposide—urinary bladder cancer	0.000757	0.00251	CcSEcCtD
Thioridazine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000754	0.0025	CcSEcCtD
Thioridazine—Constipation—Gemcitabine—urinary bladder cancer	0.000752	0.0025	CcSEcCtD
Thioridazine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000752	0.0025	CcSEcCtD
Thioridazine—Pancytopenia—Methotrexate—urinary bladder cancer	0.000751	0.00249	CcSEcCtD
Thioridazine—Asthma—Epirubicin—urinary bladder cancer	0.00074	0.00246	CcSEcCtD
Thioridazine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000735	0.00244	CcSEcCtD
Thioridazine—Tachycardia—Etoposide—urinary bladder cancer	0.000733	0.00243	CcSEcCtD
Thioridazine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000733	0.00243	CcSEcCtD
Thioridazine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000726	0.00241	CcSEcCtD
Thioridazine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000725	0.00241	CcSEcCtD
Thioridazine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000722	0.0024	CcSEcCtD
Thioridazine—Anorexia—Etoposide—urinary bladder cancer	0.000716	0.00238	CcSEcCtD
Thioridazine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000715	0.00238	CcSEcCtD
Thioridazine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000713	0.00237	CcSEcCtD
Thioridazine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000713	0.00237	CcSEcCtD
Thioridazine—Drowsiness—Methotrexate—urinary bladder cancer	0.000705	0.00234	CcSEcCtD
Thioridazine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000703	0.00233	CcSEcCtD
Thioridazine—Hypotension—Etoposide—urinary bladder cancer	0.000702	0.00233	CcSEcCtD
Thioridazine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000695	0.00231	CcSEcCtD
Thioridazine—Asthma—Doxorubicin—urinary bladder cancer	0.000685	0.00227	CcSEcCtD
Thioridazine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000684	0.00227	CcSEcCtD
Thioridazine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000678	0.00225	CcSEcCtD
Thioridazine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000676	0.00224	CcSEcCtD
Thioridazine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000676	0.00224	CcSEcCtD
Thioridazine—Weight increased—Epirubicin—urinary bladder cancer	0.000674	0.00224	CcSEcCtD
Thioridazine—Somnolence—Etoposide—urinary bladder cancer	0.000668	0.00222	CcSEcCtD
Thioridazine—Vomiting—Thiotepa—urinary bladder cancer	0.000665	0.00221	CcSEcCtD
Thioridazine—Drowsiness—Epirubicin—urinary bladder cancer	0.00066	0.00219	CcSEcCtD
Thioridazine—Rash—Thiotepa—urinary bladder cancer	0.000659	0.00219	CcSEcCtD
Thioridazine—Dermatitis—Thiotepa—urinary bladder cancer	0.000659	0.00219	CcSEcCtD
Thioridazine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000658	0.00219	CcSEcCtD
Thioridazine—Headache—Thiotepa—urinary bladder cancer	0.000655	0.00218	CcSEcCtD
Thioridazine—Decreased appetite—Etoposide—urinary bladder cancer	0.000653	0.00217	CcSEcCtD
Thioridazine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000651	0.00216	CcSEcCtD
Thioridazine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000648	0.00215	CcSEcCtD
Thioridazine—Jaundice—Epirubicin—urinary bladder cancer	0.000643	0.00214	CcSEcCtD
Thioridazine—Constipation—Etoposide—urinary bladder cancer	0.000642	0.00213	CcSEcCtD
Thioridazine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000637	0.00212	CcSEcCtD
Thioridazine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000625	0.00208	CcSEcCtD
Thioridazine—Weight increased—Doxorubicin—urinary bladder cancer	0.000623	0.00207	CcSEcCtD
Thioridazine—Nausea—Thiotepa—urinary bladder cancer	0.000621	0.00206	CcSEcCtD
Thioridazine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000619	0.00206	CcSEcCtD
Thioridazine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000616	0.00205	CcSEcCtD
Thioridazine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000611	0.00203	CcSEcCtD
Thioridazine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000604	0.00201	CcSEcCtD
Thioridazine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000602	0.002	CcSEcCtD
Thioridazine—Jaundice—Doxorubicin—urinary bladder cancer	0.000595	0.00198	CcSEcCtD
Thioridazine—Body temperature increased—Etoposide—urinary bladder cancer	0.000594	0.00197	CcSEcCtD
Thioridazine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000592	0.00196	CcSEcCtD
Thioridazine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000584	0.00194	CcSEcCtD
Thioridazine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00057	0.00189	CcSEcCtD
Thioridazine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000561	0.00186	CcSEcCtD
Thioridazine—Vomiting—Gemcitabine—urinary bladder cancer	0.000559	0.00186	CcSEcCtD
Thioridazine—Mental disorder—Methotrexate—urinary bladder cancer	0.000555	0.00184	CcSEcCtD
Thioridazine—Rash—Gemcitabine—urinary bladder cancer	0.000555	0.00184	CcSEcCtD
Thioridazine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000554	0.00184	CcSEcCtD
Thioridazine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000553	0.00184	CcSEcCtD
Thioridazine—Erythema—Methotrexate—urinary bladder cancer	0.000551	0.00183	CcSEcCtD
Thioridazine—Headache—Gemcitabine—urinary bladder cancer	0.000551	0.00183	CcSEcCtD
Thioridazine—Vomiting—Fluorouracil—urinary bladder cancer	0.00055	0.00183	CcSEcCtD
Thioridazine—Rash—Fluorouracil—urinary bladder cancer	0.000545	0.00181	CcSEcCtD
Thioridazine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000545	0.00181	CcSEcCtD
Thioridazine—Headache—Fluorouracil—urinary bladder cancer	0.000542	0.0018	CcSEcCtD
Thioridazine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00054	0.00179	CcSEcCtD
Thioridazine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000529	0.00176	CcSEcCtD
Thioridazine—Nausea—Gemcitabine—urinary bladder cancer	0.000522	0.00173	CcSEcCtD
Thioridazine—Vomiting—Cisplatin—urinary bladder cancer	0.000521	0.00173	CcSEcCtD
Thioridazine—Vision blurred—Methotrexate—urinary bladder cancer	0.00052	0.00173	CcSEcCtD
Thioridazine—Mental disorder—Epirubicin—urinary bladder cancer	0.000519	0.00172	CcSEcCtD
Thioridazine—Rash—Cisplatin—urinary bladder cancer	0.000517	0.00172	CcSEcCtD
Thioridazine—Dermatitis—Cisplatin—urinary bladder cancer	0.000516	0.00171	CcSEcCtD
Thioridazine—Erythema—Epirubicin—urinary bladder cancer	0.000516	0.00171	CcSEcCtD
Thioridazine—Diarrhoea—Etoposide—urinary bladder cancer	0.000514	0.00171	CcSEcCtD
Thioridazine—Nausea—Fluorouracil—urinary bladder cancer	0.000514	0.00171	CcSEcCtD
Thioridazine—Anaemia—Methotrexate—urinary bladder cancer	0.00051	0.00169	CcSEcCtD
Thioridazine—Leukopenia—Methotrexate—urinary bladder cancer	0.000493	0.00164	CcSEcCtD
Thioridazine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00049	0.00163	CcSEcCtD
Thioridazine—Nausea—Cisplatin—urinary bladder cancer	0.000487	0.00162	CcSEcCtD
Thioridazine—Vision blurred—Epirubicin—urinary bladder cancer	0.000486	0.00161	CcSEcCtD
Thioridazine—Mental disorder—Doxorubicin—urinary bladder cancer	0.00048	0.0016	CcSEcCtD
Thioridazine—Vomiting—Etoposide—urinary bladder cancer	0.000478	0.00159	CcSEcCtD
Thioridazine—Erythema—Doxorubicin—urinary bladder cancer	0.000477	0.00158	CcSEcCtD
Thioridazine—Anaemia—Epirubicin—urinary bladder cancer	0.000477	0.00158	CcSEcCtD
Thioridazine—Agitation—Epirubicin—urinary bladder cancer	0.000474	0.00157	CcSEcCtD
Thioridazine—Rash—Etoposide—urinary bladder cancer	0.000474	0.00157	CcSEcCtD
Thioridazine—Dermatitis—Etoposide—urinary bladder cancer	0.000473	0.00157	CcSEcCtD
Thioridazine—Headache—Etoposide—urinary bladder cancer	0.000471	0.00156	CcSEcCtD
Thioridazine—Leukopenia—Epirubicin—urinary bladder cancer	0.000462	0.00153	CcSEcCtD
Thioridazine—Confusional state—Methotrexate—urinary bladder cancer	0.000454	0.00151	CcSEcCtD
Thioridazine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00045	0.00149	CcSEcCtD
Thioridazine—Nausea—Etoposide—urinary bladder cancer	0.000446	0.00148	CcSEcCtD
Thioridazine—Anaemia—Doxorubicin—urinary bladder cancer	0.000441	0.00146	CcSEcCtD
Thioridazine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00044	0.00146	CcSEcCtD
Thioridazine—Agitation—Doxorubicin—urinary bladder cancer	0.000439	0.00146	CcSEcCtD
Thioridazine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000435	0.00144	CcSEcCtD
Thioridazine—Anorexia—Methotrexate—urinary bladder cancer	0.000429	0.00142	CcSEcCtD
Thioridazine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000427	0.00142	CcSEcCtD
Thioridazine—Confusional state—Epirubicin—urinary bladder cancer	0.000425	0.00141	CcSEcCtD
Thioridazine—Oedema—Epirubicin—urinary bladder cancer	0.000421	0.0014	CcSEcCtD
Thioridazine—Hypotension—Methotrexate—urinary bladder cancer	0.00042	0.0014	CcSEcCtD
Thioridazine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000412	0.00137	CcSEcCtD
Thioridazine—Tachycardia—Epirubicin—urinary bladder cancer	0.000411	0.00136	CcSEcCtD
Thioridazine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000407	0.00135	CcSEcCtD
Thioridazine—Anorexia—Epirubicin—urinary bladder cancer	0.000401	0.00133	CcSEcCtD
Thioridazine—Somnolence—Methotrexate—urinary bladder cancer	0.0004	0.00133	CcSEcCtD
Thioridazine—Hypotension—Epirubicin—urinary bladder cancer	0.000393	0.00131	CcSEcCtD
Thioridazine—Confusional state—Doxorubicin—urinary bladder cancer	0.000393	0.0013	CcSEcCtD
Thioridazine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000391	0.0013	CcSEcCtD
Thioridazine—Oedema—Doxorubicin—urinary bladder cancer	0.00039	0.00129	CcSEcCtD
Thioridazine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000381	0.00127	CcSEcCtD
Thioridazine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00038	0.00126	CcSEcCtD
Thioridazine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000377	0.00125	CcSEcCtD
Thioridazine—Somnolence—Epirubicin—urinary bladder cancer	0.000374	0.00124	CcSEcCtD
Thioridazine—Anorexia—Doxorubicin—urinary bladder cancer	0.000371	0.00123	CcSEcCtD
Thioridazine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000371	0.00123	CcSEcCtD
Thioridazine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000366	0.00122	CcSEcCtD
Thioridazine—Hypotension—Doxorubicin—urinary bladder cancer	0.000364	0.00121	CcSEcCtD
Thioridazine—Constipation—Epirubicin—urinary bladder cancer	0.00036	0.0012	CcSEcCtD
Thioridazine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000356	0.00118	CcSEcCtD
Thioridazine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000347	0.00115	CcSEcCtD
Thioridazine—Somnolence—Doxorubicin—urinary bladder cancer	0.000346	0.00115	CcSEcCtD
Thioridazine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000339	0.00112	CcSEcCtD
Thioridazine—Constipation—Doxorubicin—urinary bladder cancer	0.000333	0.00111	CcSEcCtD
Thioridazine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000333	0.00111	CcSEcCtD
Thioridazine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000331	0.0011	CcSEcCtD
Thioridazine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000321	0.00107	CcSEcCtD
Thioridazine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00031	0.00103	CcSEcCtD
Thioridazine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000308	0.00102	CcSEcCtD
Thioridazine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000308	0.00102	CcSEcCtD
Thioridazine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000288	0.000957	CcSEcCtD
Thioridazine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000287	0.000953	CcSEcCtD
Thioridazine—Vomiting—Methotrexate—urinary bladder cancer	0.000286	0.00095	CcSEcCtD
Thioridazine—Rash—Methotrexate—urinary bladder cancer	0.000284	0.000942	CcSEcCtD
Thioridazine—Dermatitis—Methotrexate—urinary bladder cancer	0.000283	0.000941	CcSEcCtD
Thioridazine—Headache—Methotrexate—urinary bladder cancer	0.000282	0.000936	CcSEcCtD
Thioridazine—Vomiting—Epirubicin—urinary bladder cancer	0.000268	0.000889	CcSEcCtD
Thioridazine—Nausea—Methotrexate—urinary bladder cancer	0.000267	0.000887	CcSEcCtD
Thioridazine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000267	0.000885	CcSEcCtD
Thioridazine—Rash—Epirubicin—urinary bladder cancer	0.000265	0.000881	CcSEcCtD
Thioridazine—Dermatitis—Epirubicin—urinary bladder cancer	0.000265	0.000881	CcSEcCtD
Thioridazine—Headache—Epirubicin—urinary bladder cancer	0.000264	0.000876	CcSEcCtD
Thioridazine—Nausea—Epirubicin—urinary bladder cancer	0.00025	0.00083	CcSEcCtD
Thioridazine—Vomiting—Doxorubicin—urinary bladder cancer	0.000248	0.000822	CcSEcCtD
Thioridazine—Rash—Doxorubicin—urinary bladder cancer	0.000246	0.000816	CcSEcCtD
Thioridazine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000245	0.000815	CcSEcCtD
Thioridazine—Headache—Doxorubicin—urinary bladder cancer	0.000244	0.00081	CcSEcCtD
Thioridazine—Nausea—Doxorubicin—urinary bladder cancer	0.000231	0.000768	CcSEcCtD
Thioridazine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.01e-05	0.000126	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	2e-05	0.000126	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.99e-05	0.000125	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.99e-05	0.000125	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.99e-05	0.000125	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.98e-05	0.000124	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—SRC—urinary bladder cancer	1.98e-05	0.000124	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—SRC—urinary bladder cancer	1.98e-05	0.000124	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.97e-05	0.000124	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	0.000123	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	0.000123	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	1.95e-05	0.000123	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—IL2—urinary bladder cancer	1.95e-05	0.000123	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.95e-05	0.000122	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.95e-05	0.000122	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.94e-05	0.000122	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.92e-05	0.00012	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.91e-05	0.00012	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.91e-05	0.00012	CbGpPWpGaD
Thioridazine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.91e-05	0.00012	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.91e-05	0.00012	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	1.91e-05	0.00012	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	1.9e-05	0.000119	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.89e-05	0.000119	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.89e-05	0.000118	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.88e-05	0.000118	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.88e-05	0.000118	CbGpPWpGaD
Thioridazine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.88e-05	0.000118	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	1.88e-05	0.000118	CbGpPWpGaD
Thioridazine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.87e-05	0.000118	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.87e-05	0.000117	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.87e-05	0.000117	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	1.85e-05	0.000116	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.85e-05	0.000116	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.85e-05	0.000116	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	1.85e-05	0.000116	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	1.85e-05	0.000116	CbGpPWpGaD
Thioridazine—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	1.84e-05	0.000116	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.84e-05	0.000116	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.84e-05	0.000116	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.84e-05	0.000115	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.84e-05	0.000115	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	1.84e-05	0.000115	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.83e-05	0.000115	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.81e-05	0.000114	CbGpPWpGaD
Thioridazine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	1.8e-05	0.000113	CbGpPWpGaD
Thioridazine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.77e-05	0.000111	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—MYC—urinary bladder cancer	1.77e-05	0.000111	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—MYC—urinary bladder cancer	1.77e-05	0.000111	CbGpPWpGaD
Thioridazine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.77e-05	0.000111	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	1.76e-05	0.000111	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	1.76e-05	0.00011	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.76e-05	0.00011	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.75e-05	0.00011	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—EP300—urinary bladder cancer	1.75e-05	0.00011	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.75e-05	0.00011	CbGpPWpGaD
Thioridazine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.74e-05	0.00011	CbGpPWpGaD
Thioridazine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	1.74e-05	0.000109	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	0.000109	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.74e-05	0.000109	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.74e-05	0.000109	CbGpPWpGaD
Thioridazine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.74e-05	0.000109	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	1.73e-05	0.000109	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	1.73e-05	0.000109	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	1.73e-05	0.000108	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.72e-05	0.000108	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.72e-05	0.000108	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.72e-05	0.000108	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.72e-05	0.000108	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.71e-05	0.000107	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—SRC—urinary bladder cancer	1.7e-05	0.000107	CbGpPWpGaD
Thioridazine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	1.7e-05	0.000107	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	1.7e-05	0.000107	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.69e-05	0.000106	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.000106	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.68e-05	0.000105	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.67e-05	0.000105	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.67e-05	0.000105	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000105	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000105	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.66e-05	0.000104	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.65e-05	0.000104	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.64e-05	0.000103	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	1.64e-05	0.000103	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.64e-05	0.000103	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.63e-05	0.000102	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.63e-05	0.000102	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.61e-05	0.000101	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.6e-05	0.0001	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.6e-05	0.0001	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.6e-05	0.0001	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.6e-05	0.0001	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.59e-05	9.97e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.58e-05	9.94e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.58e-05	9.92e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.58e-05	9.91e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.57e-05	9.88e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.57e-05	9.87e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.57e-05	9.86e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.57e-05	9.86e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	9.84e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.57e-05	9.83e-05	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.56e-05	9.81e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.56e-05	9.78e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.54e-05	9.68e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.53e-05	9.62e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.53e-05	9.62e-05	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.53e-05	9.58e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.52e-05	9.52e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.51e-05	9.5e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	1.51e-05	9.5e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.51e-05	9.46e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.51e-05	9.46e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.51e-05	9.45e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.5e-05	9.44e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	1.5e-05	9.44e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.5e-05	9.4e-05	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.49e-05	9.37e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.49e-05	9.35e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.49e-05	9.33e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.48e-05	9.32e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.48e-05	9.29e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.48e-05	9.26e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.47e-05	9.25e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.47e-05	9.25e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.47e-05	9.24e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.46e-05	9.19e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.46e-05	9.15e-05	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1.46e-05	9.14e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.46e-05	9.14e-05	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—TP53—urinary bladder cancer	1.45e-05	9.13e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.45e-05	9.1e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.45e-05	9.08e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.44e-05	9.02e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	1.43e-05	9e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.42e-05	8.94e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.42e-05	8.91e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Metabolism—EP300—urinary bladder cancer	1.42e-05	8.89e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.41e-05	8.87e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.41e-05	8.85e-05	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.41e-05	8.85e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.41e-05	8.85e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.4e-05	8.77e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	1.39e-05	8.75e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.39e-05	8.75e-05	CbGpPWpGaD
Thioridazine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	1.39e-05	8.74e-05	CbGpPWpGaD
Thioridazine—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	1.39e-05	8.73e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.39e-05	8.72e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.39e-05	8.71e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.39e-05	8.7e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.38e-05	8.69e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.38e-05	8.66e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.37e-05	8.61e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.37e-05	8.61e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.37e-05	8.6e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.37e-05	8.58e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.36e-05	8.56e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.36e-05	8.56e-05	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.36e-05	8.56e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.36e-05	8.55e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.35e-05	8.5e-05	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.35e-05	8.48e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.35e-05	8.46e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.34e-05	8.43e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.34e-05	8.43e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.34e-05	8.43e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.34e-05	8.41e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.34e-05	8.4e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.34e-05	8.39e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.32e-05	8.3e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.32e-05	8.28e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.31e-05	8.24e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.31e-05	8.2e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.3e-05	8.17e-05	CbGpPWpGaD
Thioridazine—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.3e-05	8.16e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.3e-05	8.15e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.29e-05	8.07e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.29e-05	8.07e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.28e-05	8.06e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	1.28e-05	8.02e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.28e-05	8.02e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.27e-05	8e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.27e-05	7.94e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.26e-05	7.92e-05	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.25e-05	7.87e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	1.25e-05	7.85e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.25e-05	7.84e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.24e-05	7.81e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	1.24e-05	7.8e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.24e-05	7.79e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.24e-05	7.78e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	1.22e-05	7.67e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.21e-05	7.61e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.21e-05	7.57e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	7.57e-05	CbGpPWpGaD
Thioridazine—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	7.52e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.19e-05	7.5e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.18e-05	7.43e-05	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.18e-05	7.4e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-05	7.25e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.15e-05	7.23e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.15e-05	7.23e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	7.2e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.13e-05	7.12e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	1.13e-05	7.1e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.13e-05	7.07e-05	CbGpPWpGaD
Thioridazine—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.12e-05	7.05e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	1.11e-05	6.99e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.11e-05	6.97e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	6.96e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.11e-05	6.96e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	1.11e-05	6.95e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.1e-05	6.9e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-05	6.83e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.09e-05	6.82e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.08e-05	6.77e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.07e-05	6.73e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-05	6.68e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.05e-05	6.6e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.05e-05	6.58e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	1.05e-05	6.56e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	1.03e-05	6.47e-05	CbGpPWpGaD
Thioridazine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-05	6.47e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	6.46e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	1.03e-05	6.44e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	6.44e-05	CbGpPWpGaD
Thioridazine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-05	6.44e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.01e-05	6.33e-05	CbGpPWpGaD
Thioridazine—CYP2C19—Metabolism—EP300—urinary bladder cancer	1e-05	6.3e-05	CbGpPWpGaD
Thioridazine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	9.82e-06	6.16e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.67e-06	6.07e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.59e-06	6.02e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	9.53e-06	5.98e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	9.46e-06	5.94e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.4e-06	5.9e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	9.31e-06	5.84e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	9.29e-06	5.83e-05	CbGpPWpGaD
Thioridazine—CYP2D6—Metabolism—EP300—urinary bladder cancer	9.22e-06	5.79e-05	CbGpPWpGaD
Thioridazine—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.14e-06	5.74e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	9.14e-06	5.74e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	9.12e-06	5.72e-05	CbGpPWpGaD
Thioridazine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	9.05e-06	5.68e-05	CbGpPWpGaD
Thioridazine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	8.9e-06	5.59e-05	CbGpPWpGaD
Thioridazine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	8.89e-06	5.58e-05	CbGpPWpGaD
Thioridazine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	8.74e-06	5.49e-05	CbGpPWpGaD
Thioridazine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	8.72e-06	5.47e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	8.47e-06	5.32e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.19e-06	5.14e-05	CbGpPWpGaD
Thioridazine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	8.1e-06	5.09e-05	CbGpPWpGaD
Thioridazine—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.81e-06	4.91e-05	CbGpPWpGaD
